Article · Volume 3, Issue 4 · pp. 353–355
Istaroxime: A rising star in acute heart failure
Suruchi Aditya1, Aditya Rattan2
- 1Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Chandigarh, Punjab.
- 2Department of Cardiology, Heartline, Panchkula, Haryana, India Molecules of the Millennium, Institute of Dental Sciences, Chandigarh, Punjab.
Abstract
Heart failure in India is a growing epidemic. Around 30 to 40% of patients die from heart failure within one year of receiving the diagnosis. Currently available inotropes have not only failed to show consistent results but are also associated with adverse outcomes. Istaroxime is a novel intravenous agent with luso‑inotropic properties that acts by inhibition of Na+/K+ adenosine triphosphatase and stimulation of sarco/ endoplasmic reticulum calcium ATPase isoform 2. In clinical studies, it significantly decreased left ventricular end diastolic pressure, pulmonary capillary wedge pressure, heart rate and increased systolic blood pressure and cardiac index with no change in neurohormones, renal function or troponin I. Istaroxime is a promising alternative for patients presenting with acute heart failure syndrome for whom the therapeutic options are currently limited.
Keywords: Acute heart failure syndromes; lusitropic; sarco/endoplasmic reticulum calcium
The full text of this article is available as a PDF. Open the PDF.